Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 16, 2025

Phase 2 Study of Relmacabtagene Autoleucel (CD19 CAR-T) for Relapsed/Refractory Mantle Cell Lymphoma in Chinese Adults.

View Full Paper
Ask AI
Bookmark
Share

Authors

YXYan XiePeking UniversityKZKeshu ZhouWuhan UniversityLLLanfang LiMinistry of Education of the People's Republic of China

Discussion

Loading...

Member takes

Implication

Phase 2 trial shows 71.19% response rate in 70 patients with R/R mantle cell lymphoma, indicating potential effectiveness of CD19 CAR-T therapy.

Key Points

  • The study found an objective response rate of 71.19% at 3 months following treatment with relmacabtagene autoleucel.
  • Complete response was achieved by 59.32% of participants, indicating effective treatment outcomes for R/R mantle cell lymphoma.
  • This multicenter, open-label study involved 70 heavily pretreated patients with prior therapies ranging from 1-9.
  • High-grade adverse events like neutropenia were common, but severe complications resolved fully, supporting the therapy's manageable safety profile.

Cite This Study

Xie et al. (2025) studied this question.

synapsesocial.com/papers/68a3688b0a429f797332ddachttps://doi.org/10.1182/bloodadvances.2024015763
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification2014 · 5,746 citations
  2. 2ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells2018 · 3,694 citations
  3. 3Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry2023 · 85 citations
  4. 4KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma2020 · 1,879 citations
  5. 5Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium2023 · 192 citations